References
- Fujita T , DoiharaH, KawasakiKet al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br. J. Cancer94(2), 247–252 (2006).
- Spector NL , BlackwellKL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol.27(34). 5838–5847 (2009).
- Slamon DJ , Leyland-JonesB, ShakSet al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
- Marty M , CognettiF, MaraninchiDet al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol.23(19), 4265–4274 (2005).
- Sendur MA , AksoyS, AltundagK. Pertuzumab in HER2-positive breast cancer. Curr. Med. Res. Opin.28(10), 1709–1176 (2012).
- Baselga J , CortesJ, KimSBet al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med.366(2), 109–119 (2012).
- Swain SM , KimSB, CortesJet al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Oncol.14(6), 461–471 (2013).
- Gianni L , PienkowskiT, ImYHet al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, Phase 2 trial. Lancet Oncol.13(1), 25–32 (2012).
- Schneeweiss A , ChiaS, HickishTet al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized Phase II cardiac safety study (TRYPHAENA). Ann. Oncol.24(9), 2278–2284 (2013).
- Seidman A , HudisC, PierriMKet al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol.20(5), 1215–1221 (2002).
- Chen T , XuT, LiYet al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat. Rev.37(4), 312–320 (2011).
- Scheuer W , FriessT, BurtscherH, BossenmaierB, EndlJ, HasmannM. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res.69(24), 9330–9336 (2009).
- Agus DB , GordonMS, TaylorCet al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol.23(11), 2534–2543 (2005).
- Baselga J , GelmonKA, VermaSet al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol.28(7), 1138–1144 (2010).
- Gianni L , LladóA, BianchiGet al. Open-label, Phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol.28(7), 1131–1137 (2010).
- Datko F , AndreaDG, DicklerMet al. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer (MBC). J. Clin. Oncol.31(Suppl.), 606 (2013).
- Garg A , LiJ, ClarkE, KnottA. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemother. Pharmacol.72(5), 1133–1141 (2013).
- Erickson SL , O’SheaKS, GhaboosiNet al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development124(24), 4999–5011 (1997).
- Lee KF , SimonH, ChenH, BatesB, HungMC, HauserC. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature378(6555), 394–398 (1995).
- Sendur MA , AksoyS, AltundagK. Cardiotoxicity of novel HER2-targeted therapies. Curr. Med. Res. Opin.29(8), 1015–1024 (2013).
- Fedele C , RiccioG, CoppolaCet al. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res. Treat.133(2), 511–521 (2012).